Document Type : Original Article
Keywords
| 1. | |
| 2. |
Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders. Trends Neurosci 2000;23:359-65. ![]() [PUBMED] |
| 3. |
Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf) 2010;198:313-24. ![]() [PUBMED] |
| 4. |
Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6. ![]() [PUBMED] |
| 5. | |
| 6. |
Thorpe AJ, Doane DF, Sweet DC, Beverly JL, Kotz CM. Orexin A in the rostrolateral hypothalamic area induces feeding by modulating GABAergic transmission. Brain Res 2006;1125:60-6. ![]() [PUBMED] |
| 7. | |
| 8. |
Morales A, Bonnet C, Bourgoin N, Touvier T, Nadam J, Laglaine A, et al. Unexpected expression of orexin-B in basal conditions and increased levels in the adult rat hippocampus during pilocarpine-induced epileptogenesis. Brain Res 2006;1109:164-75. ![]() [PUBMED] |
| 9. | |
| 10. |
Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M, et al. Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep 2012;64:1427-33. ![]() |
| 11. | |
| 12. |
Goudarzi E, Elahdadi Salmani M, Lashkarbolouki T, Goudarzi I. Hippocampal orexin receptors inactivation reduces PTZ induced seizures of male rats. Pharmacol Biochem Behav 2015;130:77-83. ![]() [PUBMED] |
| 13. | |
| 14. |
Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice. Sleep 2016;39:357-68. ![]() [PUBMED] |
| 15. |
Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010;51 Suppl 3:154-9. ![]() [PUBMED] |
| 16. |
Lu YJ, Zhou J, Zhang SM, Zhang HY, Zheng XX. Inhibitory effects of jujuboside A on EEG and hippocampal glutamate in hyperactive rat. J Zhejiang Univ Sci B 2005;6:265-71. ![]() [PUBMED] |
| 17. | |
| 18. | |
| 19. |
Yu W, Smith AB, Pilitsis J, Shin DS. Isovaline attenuates epileptiform activity and seizure behavior in 4-aminopyridine treated rats. Epilepsy Res 2014;108:331-5. ![]() [PUBMED] |
| 20. | |
| 21. |
Salah A, Perkins KL. Persistent ictal-like activity in rat entorhinal/perirhinal cortex following washout of 4-aminopyridine. Epilepsy Res 2011;94:163-76. ![]() [PUBMED] |
| 22. | |
| 23. | |
| 24. |
Saito T, Sakamoto K, Koizumi K, Stewart M. Repeatable focal seizure suppression: A rat preparation to study consequences of seizure activity based on urethane anesthesia and reversible carotid artery occlusion. J Neurosci Methods 2006;155:241-50. ![]() [PUBMED] |
| 25. |
Sakamoto K, Saito T, Orman R, Koizumi K, Lazar J, Salciccioli L, et al. Autonomic consequences of kainic acid-induced limbic cortical seizures in rats: Peripheral autonomic nerve activity, acute cardiovascular changes, and death. Epilepsia 2008;49:982-96. ![]() [PUBMED] |
| 26. |
Zhang DX, Bertram EH. Suppressing limbic seizures by stimulating medial dorsal thalamic nucleus: Factors for efficacy. Epilepsia 2015;56:479-88. ![]() [PUBMED] |
| 27. |
Cain DP, Raithby A, Corcoran ME. Urethane anesthesia blocks the development and expression of kindled seizures. Life Sci 1989;44:1201-6. ![]() [PUBMED] |
| 28. |
Stringer JL. Amygdala stimulation produces two types of hippocampal afterdischarges in the urethane-anesthetized rat. Brain Res 1992;591:103-8. ![]() [PUBMED] |
| 29. |
Hara K, Harris RA. The anesthetic mechanism of urethane: The effects on neurotransmitter-gated ion channels. Anesth Analg 2002;94:313-8. ![]() [PUBMED] |
| 30. |
Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: A revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. ![]() [PUBMED] |
| 31. |
Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT, et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci 2001;21:RC168. ![]() [PUBMED] |
| 32. |
Li Y, van den Pol AN. Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. J Neurosci 2006;26:13037-47. ![]() [PUBMED] |
| 33. |
Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. ![]() [PUBMED] |
| 34. | |
| 35. |
Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, et al. SB-334867-A: The first selective orexin-1 receptor antagonist. Br J Pharmacol 2001;132:1179-82. ![]() [PUBMED] |
| 36. | |
| 37. |
Rajasekaran K, Zanelli SA, Goodkin HP. Lessons from the laboratory: The pathophysiology, and consequences of status epilepticus. Semin Pediatr Neurol 2010;17:136-43. ![]() [PUBMED] |
| 38. | |
| 39. |
Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. Mesial temporal lobe epilepsy: Pathogenesis, induced rodent models and lesions. Toxicol Pathol 2007;35:984-99. ![]() [PUBMED] |